Image

Anti-Müllerian Hormone in Breast Cancer Clinical Practice

Anti-Müllerian Hormone in Breast Cancer Clinical Practice

Recruiting
20-55 years
Female
Phase N/A

Powered by AI

Overview

This study aims to evaluate serum anti-Müllerian hormone (AMH) levels and complementary hormonal parameters, including follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4), in women with breast cancer and healthy female controls.

The study will generate preliminary real-world data on AMH and related hormonal parameters and assess the feasibility of implementing AMH testing into routine clinical practice.

Description

The study will include women aged 20-55 years. Patients with breast cancer will be enrolled at different stages of their disease and treatment, including newly diagnosed treatment-naive patients, patients who have completed chemotherapy, patients receiving endocrine therapy without prior chemotherapy, and patients undergoing follow-up after treatment.

In patients with breast cancer, hormonal measurements will be obtained as part of routine clinical care, based on the treating physician's decision. No additional study-specific blood sampling or interventions will be performed. Relevant clinical data will be collected from medical records.

Healthy volunteers will undergo a single blood sampling procedure and complete a brief questionnaire covering gynecological history, smoking status, and body mass index (BMI).

The hormonal assessment will include serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4).

The collected data will be used to describe hormonal profiles in both study populations and assess the feasibility of routine AMH testing in clinical practice. The findings may provide preliminary data for future research on the clinical utility of AMH in women with breast cancer.

Eligibility

Inclusion Criteria:

  • Women aged 20-55 years.
  • Patients with a diagnosis of breast cancer at any of the specified stages of treatment or follow-up, or healthy female volunteers.
  • Blood sampling as part of routine clinical care (breast cancer patients) or willingness to undergo a single blood draw (healthy volunteers).

Exclusion Criteria:

  • Inability or unwillingness to participate in the study.

Study details
    Breast Cancer

NCT07896772

Masaryk Memorial Cancer Institute

31 October 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.